In Conversation With… Kathy Perez
“When patients can track their own experience of steroid‑toxicity and take that data straight into the clinic, they stop being passive recipients and start driving the conversation.” Clinicians know ...
In Conversation With… Albert Whangbo, PhD
“Steroids are cheap and effective in the short term. Convincing payers that steroid-sparing therapies are worth the upfront cost is still a practical challenge.” Albert Whangbo, PhD, leads the global ...
In Conversation With… Lori McLeod, PhD
“Behind every data point is a patient story - and it’s the responsibility of healthcare researchers and practitioners to listen, measure, and respond.” As Vice President of Patient-Centered Outcomes ...
In Conversation With… Professor Ailsa Hart
“We have to make the case that avoiding steroids isn’t just about following guidelines - it’s about protecting the long-term health of our patients.” Steroids remain a cornerstone of inflammatory ...
In Conversation With… Tonya Winders
"For more than 20 years, we've had monoclonal antibodies for asthma, yet only one in five eligible patients are on them. And in more than 80 countries, there isn’t a single biologic available." The ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
